Around 38% of type 2 diabetes patients skip prescribed medications, driven by patient, socioeconomic, disease chronicity, comorbidities, and system barriers, leading to higher HbA1c, amplified micro/macrovascular risks, hospitalizations, mortality, and ballooning healthcare costs. Adherence assessment spans self-reports to emerging biochemical tests, while interventions like pharmacist-led care, fixed-dose combinations shine; tech/motivational tools show mixed results. Tailored multifaceted approaches - educational, behavioral (e.g., CBT), financial, shared decision-making excel long-term, especially for multimorbid cases, demanding scalable personalization for equitable impact. Boost adherence now transform T2D outcomes and costs!
To read more click here . ##Reference## Highton, P.J., Funnell, M.P., Gupta, P. et al. Improving medication adherence in type 2 diabetes: strategies for…
